| __timestamp | Alnylam Pharmaceuticals, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 11606000000 |
| Thursday, January 1, 2015 | 60610000 | 10313000000 |
| Friday, January 1, 2016 | 89354000 | 9762000000 |
| Sunday, January 1, 2017 | 199365000 | 9830000000 |
| Monday, January 1, 2018 | 382359000 | 10102000000 |
| Tuesday, January 1, 2019 | 479005000 | 10615000000 |
| Wednesday, January 1, 2020 | 588420000 | 8955000000 |
| Friday, January 1, 2021 | 620639000 | 9634000000 |
| Saturday, January 1, 2022 | 770658000 | 10042000000 |
| Sunday, January 1, 2023 | 795646000 | 10504000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. Over the past decade, Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have shown a slight decline, with a peak in 2014 and a notable dip in 2020, reflecting a strategic tightening of their financial belt. In contrast, Alnylam has seen a dramatic rise, with expenses increasing by over 1,600% from 2014 to 2023, indicating aggressive expansion and investment in growth. This divergence highlights the different paths these companies have taken: Merck focusing on efficiency and Alnylam on growth. As the pharmaceutical industry continues to face challenges and opportunities, these insights into SG&A expenses offer a window into the strategic priorities of these industry leaders.
Merck & Co., Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Bio-Techne Corporation
Comparing SG&A Expenses: Merck & Co., Inc. vs Amicus Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Arrowhead Pharmaceuticals, Inc.
Merck & Co., Inc. vs MannKind Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Dynavax Technologies Corporation
Merck & Co., Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
AstraZeneca PLC and Alnylam Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.
Alnylam Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.